Winning this award is a proud moment for the entire ABL team. Our submission highlighted decades of scientific leadership, our robust viral manufacturing platforms, and our recent expansion through the Ascend Advanced Therapies merger—which now enables us to support clients from preclinical development through commercial-scale manufacturing. Being recognized among such an elite group of industry peers affirms our commitment to technical agility, collaborative partnerships, and high-quality solutions that accelerate global vaccine and therapeutic development.

This recognition reflects not only our capabilities but also our relationships—longstanding partnerships with government agencies, biotech innovators, and research collaborators who entrust ABL with some of the world’s most important programs.